INM-089 IVT formulation selected for continued developmentDemonstrated successful delivery at doses up to 10 times the ...

温哥华 - 市值221万美元的小型生物科技公司InMed Pharmaceuticals Inc. (NASDAQ: INM)宣布选定一种玻璃体内 (IVT)配方INM-089，用于进一步开发其针对干性年龄相关性黄斑变性 ...

InMed Pharmaceuticals (INM) announced the selection of an intravitreal, IVT, formulation for INM-089 as a drug candidate to be utilized in the ...

温哥华 - 市值360万美元的制药公司InMed Pharmaceuticals Inc. (NASDAQ: INM)在其专有小分子药物候选物方面取得重大进展，获得了专利合作条约 (PCT)下的国际专利。根据 InvestingPro ...

Inmed Pharmaceuticals Inc. has selected an intravitreal (IVT) formulation for INM-089 as a drug candidate to be utilized in the company’s ongoing development program targeting the treatment of dry age ...

VANCOUVER - InMed Pharmaceuticals Inc. (NASDAQ: INM), a small-cap biotech company with a market capitalization of $2.21 million, has announced the selection of an intravitreal (IVT) formulation, ...

VANCOUVER - In a significant development for its proprietary small molecule drug candidates, InMed Pharmaceuticals Inc. (NASDAQ: INM), a $3.6 million market cap pharmaceutical company dedicated to ...

InMed Pharmaceuticals shares are trading higher by 45% during Tuesday's session. The company announced that INM-901 reduced Alzheimer 's-related inflammation in a preclinical study.

INM-089 IVT formulation selected for continued developmentDemonstrated successful delivery at doses up to 10 times the projected therapeutic level, indicating a favorable pharmacokinetic profile and a ...

INM-901 significantly reduced pro-inflammatory cytokines associated with Alzheimer'sStatistically significant reduction in neurodegeneration marker, neurofilament light chain ('NfL')mRNA profile ...